BNGO (Bionano Genomics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BNGO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-21 | Albert Luderer | Interim Chief Executive | Buy | — | — |
| 2026-08-05 | Jonathan V. Dixon | General Counsel | A | — | — |
| 2026-08-05 | MARK OLDAKOWSKI | Chief Operating Officer | A | — | — |
| 2026-08-05 | Alex Reid Hastie | Chief Scientific Officer | A | — | — |
| 2026-08-05 | Mark Adamchak | Principal Accounting Officer | A | — | — |
| 2026-06-03 | MARK OLDAKOWSKI | CHIEF OPERATING OFFICER | F | — | — |
| 2026-06-03 | Mark Adamchak | Principal Accounting Officer | F | — | — |
| 2026-06-03 | Jonathan V. Dixon | GENERAL COUNSEL | F | — | — |
| 2026-06-03 | Alka Chaubey | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-05-14 | Aleksandar Rajkovic | Director | A | — | — |
| 2026-05-14 | CHRISTOPHER J TWOMEY | Director | A | — | — |
| 2026-05-14 | Kristiina MD Vuori | Director | A | — | — |
| 2026-05-14 | DAVID L BARKER | Director | A | — | — |
| 2026-05-14 | Yvonne Linney | Director | A | — | — |
| 2026-02-18 | Mark Adamchak | Principal Accounting Officer | F | — | — |
| 2026-02-18 | Jonathan V. Dixon | GENERAL COUNSEL | F | — | — |
| 2026-02-18 | Alka Chaubey | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-02-18 | R. Erik Holmlin | PRESIDENT AND CEO | F | — | — |
| 2026-02-18 | MARK OLDAKOWSKI | CHIEF OPERATING OFFICER | F | — | — |
| 2026-02-04 | Mark Adamchak | Principal Accounting Officer | A | — | — |
| 2026-02-04 | Alka Chaubey | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-02-04 | Jonathan V. Dixon | GENERAL COUNSEL | A | — | — |
| 2026-02-04 | R. Erik Holmlin | PRESIDENT AND CEO | A | — | — |
| 2026-02-04 | MARK OLDAKOWSKI | CHIEF OPERATING OFFICER | A | — | — |
| 2025-09-12 | Alka Chaubey | Chief Medical Officer | F | — | — |
| 2025-09-12 | MARK OLDAKOWSKI | Chief Operating Officer | F | — | — |
| 2025-09-12 | MARK OLDAKOWSKI | Chief Operating Officer | F | — | — |
| 2025-06-12 | Hannah Mamuszka | Director | A | — | — |
| 2025-06-12 | Kristiina MD Vuori | Director | A | — | — |
| 2025-06-12 | DAVID L BARKER | Director | A | — | — |
| 2025-06-12 | Yvonne Linney | Director | A | — | — |
| 2025-06-12 | Albert Luderer | Director | A | — | — |
| 2025-06-12 | CHRISTOPHER J TWOMEY | Director | A | — | — |
| 2025-06-12 | Aleksandar Rajkovic | Director | A | — | — |
| 2025-06-03 | Alka Chaubey | Chief Medical Officer | F | — | — |
| 2025-06-03 | MARK OLDAKOWSKI | Chief Operating Officer | F | — | — |
| 2025-06-03 | Mark Adamchak | Principal Accounting Officer | F | — | — |
| 2025-06-03 | Jonathan V. Dixon | General Counsel | F | — | — |
| 2025-06-03 | R. Erik Holmlin | President and CEO | F | — | — |
| 2025-03-18 | Alka Chaubey | Chief Medical Officer | A | — | — |
| 2025-03-18 | Jonathan V. Dixon | General Counsel | A | — | — |
| 2025-03-18 | MARK OLDAKOWSKI | Chief Operating Officer | A | — | — |
| 2025-03-18 | Mark Adamchak | Principal Accounting Officer | A | — | — |
| 2025-03-18 | R. Erik Holmlin | President and CEO | F | — | — |
| 2025-02-19 | Jonathan V. Dixon | General Counsel | F | — | — |
| 2025-02-19 | Alka Chaubey | Chief Medical Officer | F | — | — |
| 2025-02-19 | Mark Adamchak | Principal Accounting Officer | F | — | — |
| 2025-02-19 | MARK OLDAKOWSKI | Chief Operating Officer | F | — | — |
| 2025-02-19 | R. Erik Holmlin | President and CEO | F | — | — |
| 2024-10-02 | Mark Adamchak | Principal Accounting Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Interim Chief Executive | 4,000 | — |
| — | PRESIDENT AND CEO | 1,665 | — |
| — | Chief Operating Officer | 868 | — |
| — | CHIEF MEDICAL OFFICER | 620 | — |
| — | Chief Financial Officer | 267 | — |
| — | Principal Accounting Officer | 253 | — |
| — | General Counsel | 239 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BNGO quote page; the site-wide leaderboard is on the insider transactions hub.